Explore

Fructose's Role in Ovarian Cancer Metastasis Explored

Fructose's Role in Ovarian Cancer Metastasis Explored

Researchers at The Wistar Institute in Philadelphia have discovered that fructose plays a crucial role in the metastasis of ovarian cancer cells. Led by Prof. Katherine Aird, the study found that cancer cells surviving platinum-based chemotherapy remain biologically active, secreting substances that affect their environment. Fructose, a simple sugar, limits cholesterol production in neighboring cancer cells, weakening cell adhesion and facilitating metastasis. This finding is significant as metastasis is a major cause of death in ovarian cancer patients. The study suggests potential implications for treatment strategies involving cholesterol-lowering drugs like statins.

Ohio State University Identifies New Target for Glioblastoma Treatment

Ohio State University Identifies New Target for Glioblastoma Treatment

Researchers at The Ohio State University Comprehensive Cancer Center have identified a potential new target for treating glioblastoma, one of the deadliest forms of brain cancer. The study, published in Cancer Letters, highlights the role of the protein SET in making glioblastoma cells more vulnerable to treatment. By suppressing SET, researchers found that tumor formation was prevented in preclinical models. The study also explored the role of PP2A, an enzyme that glioblastoma cells block through proteins like ANP32A, CIP2A, and SET. Blocking these proteins increased the cancer cells' sensitivity to radiation, suggesting a new pathway for drug targeting. The research is still in its early stages and has not yet been tested in human patients.

Israeli Study Suggests Viagra May Inhibit Cancer Spread Through Cholesterol Pathway

Israeli Study Suggests Viagra May Inhibit Cancer Spread Through Cholesterol Pathway

A recent study conducted by researchers at the Weizmann Institute of Science in Israel has revealed a potential new use for sildenafil, the active ingredient in Viagra, beyond its well-known application for erectile dysfunction. The study, published in the journal Cancer Research, suggests that sildenafil may impede the metastasis of cancer cells by altering cholesterol transport within cells. This discovery highlights a previously unknown biological mechanism that could limit cancer cells' ability to spread. The research team, led by Prof. Ayelet Erez and Dr. Yarden Ariav, found that sildenafil reduces the availability of cholesterol inside cells, which is crucial for cancer cells to detach from primary tumors and establish themselves in new tissues. The study also explored the potential synergistic effect of combining sildenafil with statins, drugs that lower cholesterol production, which may further hinder cancer cell metastasis.

Illinois Patients Begin Receiving Experimental Pancreatic Cancer Drug

Illinois Patients Begin Receiving Experimental Pancreatic Cancer Drug

Patients in Illinois have started receiving an experimental drug, daraxonrasib, for treating pancreatic cancer. The drug, considered a breakthrough, extends the lives of patients with metastatic pancreatic cancer who have undergone previous treatments. In clinical trials, patients receiving daraxonrasib lived for a median of 13 months compared to six months for those on additional chemotherapy. The drug is not yet FDA-approved but is available under an expanded access program. The program allows eligible patients to receive the drug at no cost, providing hope for those with limited treatment options.

Former President Joe Biden's Prostate Cancer Progresses, Causing Significant Pain

Former President Joe Biden's Prostate Cancer Progresses, Causing Significant Pain

Former President Joe Biden's prostate cancer has advanced, causing him significant pain, according to his son, Hunter Biden. The cancer has metastasized, spreading to his bones, which has been described as very painful and debilitating. Despite the progression, Biden continues to undergo treatment and remains focused on spending time with his family. The family has been open about the challenges they face, with Hunter expressing the emotional toll it has taken on them. Medical experts note that while metastatic prostate cancer can be managed with treatments like hormone therapy and chemotherapy, it is generally not curable.

Former President Biden's Cancer Progression Raises Concerns About His Health

Former President Biden's Cancer Progression Raises Concerns About His Health

Former U.S. President Joe Biden's health has become a topic of concern following revelations from his son, Hunter Biden, that his prostate cancer has metastasized to his bones. This update was shared during an interview with BBC Newsnight, where Hunter described the condition as 'very painful and debilitating.' Joe Biden, who served as the oldest U.S. president, was diagnosed with an aggressive form of prostate cancer in May 2025, shortly after leaving office. Despite undergoing radiation and hormone therapy, the cancer has continued to spread. Biden, who had announced his candidacy for a second term in 2024, withdrew from the race following a poor debate performance against President Trump and mounting pressure from his party. His health has been a subject of scrutiny, especially given his age and the demands of the presidency.

VIRO 2026 Congress Highlights Advances in Renal Oncology Treatment Strategies

VIRO 2026 Congress Highlights Advances in Renal Oncology Treatment Strategies

The VIRO 2026 Congress, a global virtual medical event, is focusing on the latest advancements in renal oncology, particularly renal cell carcinoma and kidney cancer management. The congress gathers international experts to discuss current care standards, emerging treatment strategies, and practical approaches to improving patient outcomes. Renal cell carcinoma accounts for a significant number of cancer cases and deaths worldwide, with advanced stages posing treatment challenges. Recent therapeutic advancements, including immune checkpoint inhibitors and VEGF-targeted therapies, have reshaped care standards, though challenges remain in patient selection and long-term toxicity management.

AI Integration in Oncology Clinical Trials Enhances Efficiency and Patient Recruitment

AI Integration in Oncology Clinical Trials Enhances Efficiency and Patient Recruitment

Artificial intelligence (AI) is increasingly being integrated into oncology clinical trials, enhancing various stages of the research process. A review in Nature Reviews Clinical Oncology highlights AI's role in improving patient recruitment, eligibility assessment, and trial conduct. AI systems utilize machine learning and natural language processing to analyze electronic health records, identifying potential trial participants more efficiently. This technology aids in organizing data, flagging suitable candidates, and reducing the time between diagnosis and trial invitation. Additionally, AI supports trial conduct by extracting information from clinical records and assisting with safety monitoring. However, the review emphasizes the need for clinical verification of AI-generated suggestions due to potential data inaccuracies.

FDA Approves Pluvicto for Expanded Use in Metastatic Prostate Cancer

FDA Approves Pluvicto for Expanded Use in Metastatic Prostate Cancer

The U.S. Food and Drug Administration (FDA) has approved Pluvicto, a radioligand therapy developed by Novartis, for use in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC). This approval is based on the Phase III PSMAddition trial, which demonstrated that Pluvicto, in combination with standard care, significantly reduces the risk of disease progression or death. The therapy is now available for use across all stages of PSMA-positive metastatic prostate cancer, nearly doubling the eligible patient population. This marks a significant advancement in the treatment landscape for mHSPC, offering a new precision approach for early intervention.

New Study Maps Metastatic Cancer Cell Survival and Growth in Lungs

New Study Maps Metastatic Cancer Cell Survival and Growth in Lungs

A recent study published in Science has provided new insights into the process of cancer metastasis, particularly how liver cancer cells spread to the lungs. Researchers have developed a comprehensive spatiotemporal cellular atlas to track the progression of metastatic cancer cells. The study reveals that while most metastatic tumor cells are destroyed by the immune system, a few manage to survive and eventually grow into secondary tumors. This survival is facilitated by a high phosphoglycerate dehydrogenase (PHGDH) state, which allows the cells to evade immune detection by shutting down distress signals that would typically attract immune cells. The study involved tracking the spread of liver cancer cells in mice and comparing the findings with human samples, highlighting the ordered process of metastasis rather than a random survival contest among cells.

New Research on Vitamin C Suggests Potential Role in Cancer Treatment

New Research on Vitamin C Suggests Potential Role in Cancer Treatment

Recent studies have revisited the hypothesis proposed by Linus Pauling in the 1970s that high-dose vitamin C could slow cancer growth. While initial clinical trials using oral vitamin C showed no significant benefits, new research indicates that the method of delivery might be crucial. Intravenous administration of vitamin C allows for much higher concentrations in the bloodstream, potentially enabling it to act more like an experimental drug. Laboratory studies suggest that at these concentrations, vitamin C can generate hydrogen peroxide, selectively damaging cancer cells while sparing healthy tissue. Early-stage clinical research hints that high-dose intravenous vitamin C, when used alongside chemotherapy, may reduce treatment-related side effects and improve patient quality of life. However, these findings are not yet confirmed in large, randomized controlled trials.

Roswell Park Study Identifies Protein 'Switch' in Liposarcoma Aggressiveness

Roswell Park Study Identifies Protein 'Switch' in Liposarcoma Aggressiveness

Researchers at Roswell Park Comprehensive Cancer Center have identified a protein 'switch' that determines the aggressiveness of liposarcoma cells. Led by Dr. Blake Wilde, the study reveals that the protein PPAR-gamma influences whether stem-like cells in liposarcoma tumors develop into more aggressive or less aggressive forms. This discovery could lead to new treatment strategies for liposarcoma, a rare cancer that often recurs despite treatment. The research highlights the potential for targeting these stem-like cells to prevent the progression of manageable tumors into more dangerous forms.